跳转至内容
Merck
CN

C-904

Supelco

氯丙嗪盐酸盐标准液 盐酸盐

1.0 mg/mL in methanol (as free base), ampule of 1 mL, certified reference material, Cerilliant®

登录查看公司和协议定价


About This Item

经验公式(希尔记法):
C17H19ClN2S · HCl
CAS号:
分子量:
355.33
MDL编号:
UNSPSC代码:
41116107
NACRES:
NA.24

等级

certified reference material

质量水平

表单

liquid

特点

Snap-N-Spike®/Snap-N-Shoot®

包装

ampule of 1 mL

制造商/商品名称

Cerilliant®

浓度

1.0 mg/mL in methanol (as free base)

技术

gas chromatography (GC): suitable
liquid chromatography (LC): suitable

应用

clinical testing

包装形式

single component solution

储存温度

−20°C

SMILES字符串

Cl.CN(C)CCCN1c2ccccc2Sc3ccc(Cl)cc13

InChI

1S/C17H19ClN2S.ClH/c1-19(2)10-5-11-20-14-6-3-4-7-16(14)21-17-9-8-13(18)12-15(17)20;/h3-4,6-9,12H,5,10-11H2,1-2H3;1H

InChI key

FBSMERQALIEGJT-UHFFFAOYSA-N

一般描述

以商品名Thorazine或Largactil出售的氯丙嗪是一种用于治疗精神分裂症的典型抗精神病药。该认证的加标溶液®适合作为校准品或对照品中的起始材料用于从法医分析和临床毒理学到尿液药物检测的各种LC/MS或GC/MS应用。

法律信息

CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
CERTIFIED SPIKING SOLUTION is a registered trademark of Cerilliant Corporation
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany

警示用语:

Danger

危险分类

Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1

靶器官

Eyes

储存分类代码

3 - Flammable liquids

WGK

WGK 2

闪点(°F)

49.5 °F - closed cup

闪点(°C)

9.7 °C - closed cup

法规信息

危险化学品

从最新的版本中选择一种:

分析证书(COA)

Lot/Batch Number

抱歉,我们目前尚未线上提供该产品的COA。

如需帮助,请联系 客户支持

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Martin González-Andrade et al.
Journal of molecular recognition : JMR, 26(4), 165-174 (2013-03-05)
Protein-protein interactions play central roles in physiological and pathological processes. The bases of the mechanisms of drug action are relevant to the discovery of new therapeutic targets. This work focuses on understanding the interactions in protein-protein-ligands complexes, using proteins calmodulin
Adeline Gaillard et al.
Soins. Psychiatrie, (286)(286), 25-29 (2013-06-14)
The history of drug treatments, and particularly the discovery of certain molecules, led toan evolution in psychiatric practices. The discovery of the therapeutic properties of chlorpromazine in 1952 by Jean Delay and Pierre Deniker revolutionised the relational process between patients
Systemic uptake of chlorpromazine after delivery via retrobulbar injection.
Ruben Kuruvilla et al.
Archives of ophthalmology (Chicago, Ill. : 1960), 130(10), 1348-1349 (2012-10-10)
Antipsychotic therapy over half a century: a tale of discovery from chlorpromazine to aripiprazole.
Sridhar Natesan et al.
The National medical journal of India, 25(4), 193-195 (2013-01-03)
Stephanie L MacAllister et al.
Canadian journal of physiology and pharmacology, 91(1), 56-63 (2013-02-02)
Chlorpromazine (CPZ), a member of the largest class of first-generation antipsychotic agents, is known to cause hepatotoxicity in the form of cholestasis and hepatocellular necrosis in some patients. The mechanism of CPZ hepatotoxicity is unclear, but is thought to result

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门